Isoptin Retard (Verapamil Hydrochloride)

Verapamil selectively inhibits L‑type calcium channels on cardiac muscle and vascular smooth‑muscle cells. This blockade reduces calcium entry, leading to decreased myocardial contractility, slowed conduction through the atrioventricular node, and relaxation of arterial smooth muscle. The combined effects lower systemic vascular resistance, reduce heart rate, and improve oxygen delivery to the heart muscle.

The appropriate dose of Isoptin Retard is individualized by the prescribing clinician based on the patient’s medical condition, response to therapy, and tolerability. Dosage may be adjusted over time, and patients should follow the specific instructions provided by their healthcare professional without altering the regimen on their own.

Safety data for verapamil in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the Isoptin Retard product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Isoptin Retard (verapamil) belongs to the phenylalkylamine subclass, which has a stronger effect on cardiac conduction compared with dihydropyridine agents such as amlodipine. This makes verapamil particularly useful for arrhythmia control, while dihydropyridines are more potent vasodilators for hypertension. Choice of agent depends on the clinical priority—heart‑rate control versus pure blood‑pressure reduction.

Isoptin Retard should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not refrigerate or freeze the product.

Isoptin Retard is taken orally, usually once daily, with a full glass of water. The extended‑release tablet should be swallowed whole; it must not be split, crushed, or chewed, as this could alter the release profile and increase the risk of adverse effects. Dosing time (morning or evening) is determined by the prescriber.

The most serious adverse events include severe bradycardia, high‑grade atrioventricular block, profound hypotension, and rare cases of hepatotoxicity or life‑threatening allergic reactions. Patients should be monitored for signs of fainting, unusually slow heart rate, chest discomfort, or jaundice, and seek immediate medical attention if any of these occur.

Isoptin Retard is contraindicated in patients with severe hypotension, uncorrected second‑ or third‑degree AV block, sick sinus syndrome without a pacemaker, and in those with known hypersensitivity to verapamil or any excipients. Caution is also advised for individuals with advanced heart failure, recent myocardial infarction, or significant hepatic impairment.